Molecular intercommunication between the complement and coagulation systems.

Umme Amara, Michael A Flierl, Daniel Rittirsch, Andreas Klos, Hui Chen, Barbara Acker, Uwe B Brückner, Bo Nilsson, Florian Gebhard, John D Lambris, Markus Huber-Lang
Author Information
  1. Umme Amara: Department of Traumatology, Hand-, Plastic- and Reconstructive Surgery, University Hospital of Ulm, Ulm, Germany.

Abstract

The complement system as well as the coagulation system has fundamental clinical implications in the context of life-threatening tissue injury and inflammation. Associations between both cascades have been proposed, but the precise molecular mechanisms remain unknown. The current study reports multiple links for various factors of the coagulation and fibrinolysis cascades with the central complement components C3 and C5 in vitro and ex vivo. Thrombin, human coagulation factors (F) XIa, Xa, and IXa, and plasmin were all found to effectively cleave C3 and C5. Mass spectrometric analyses identified the cleavage products as C3a and C5a, displaying identical molecular weights as the native anaphylatoxins C3a and C5a. Cleavage products also exhibited robust chemoattraction of human mast cells and neutrophils, respectively. Enzymatic activity for C3 cleavage by the investigated clotting and fibrinolysis factors is defined in the following order: FXa > plasmin > thrombin > FIXa > FXIa > control. Furthermore, FXa-induced cleavage of C3 was significantly suppressed in the presence of the selective FXa inhibitors fondaparinux and enoxaparin in a concentration-dependent manner. Addition of FXa to human serum or plasma activated complement ex vivo, represented by the generation of C3a, C5a, and the terminal complement complex, and decreased complement hemolytic serum activity that defines exact serum concentration that results in complement-mediated lysis of 50% of sensitized sheep erythrocytes. Furthermore, in plasma from patients with multiple injuries (n = 12), a very early appearance and correlation of coagulation (thrombin-antithrombin complexes) and the complement activation product C5a was found. The present data suggest that coagulation/fibrinolysis proteases may act as natural C3 and C5 convertases, generating biologically active anaphylatoxins, linking both cascades via multiple direct interactions in terms of a complex serine protease system.

References

  1. Perit Dial Int. 2005 Jul-Aug;25(4):394-404 [PMID: 16022098]
  2. Trends Immunol. 2007 Apr;28(4):184-92 [PMID: 17336159]
  3. Immunol Rev. 2001 Apr;180:35-48 [PMID: 11414361]
  4. Blood. 2008 Feb 15;111(4):2452-61 [PMID: 18056835]
  5. Circulation. 2004 Jun 8;109(22):2698-704 [PMID: 15184294]
  6. Blood. 2004 Feb 15;103(4):1192-201 [PMID: 12907438]
  7. Blood. 2000 Oct 15;96(8):2784-92 [PMID: 11023512]
  8. J Trauma. 2008 May;64(5):1211-7; discussion 1217 [PMID: 18469643]
  9. Nat Med. 2006 Jun;12(6):682-7 [PMID: 16715088]
  10. FASEB J. 2008 Oct;22(10):3483-90 [PMID: 18587006]
  11. Mol Immunol. 2008 Oct;45(16):4057-63 [PMID: 18674818]
  12. Semin Hematol. 2001 Oct;38(4 Suppl 12):21-5 [PMID: 11735106]
  13. J Exp Med. 1981 Mar 1;153(3):665-76 [PMID: 7252410]
  14. Crit Care Med. 1997 Dec;25(12):2015-24 [PMID: 9403752]
  15. Blood. 2002 Jul 15;100(2):517-23 [PMID: 12091343]
  16. AJR Am J Roentgenol. 1979 Feb;132(2):171-6 [PMID: 105577]
  17. Shock. 2006 Oct;26(4):322-31 [PMID: 16980877]
  18. Cell Mol Life Sci. 2005 Oct;62(19-20):2161-72 [PMID: 16003488]
  19. Blood. 1986 Oct;68(4):875-80 [PMID: 3092889]
  20. J Immunol. 1999 Feb 15;162(4):2321-5 [PMID: 9973510]
  21. J Cell Sci. 2005 Jun 15;118(Pt 12):2743-53 [PMID: 15944400]
  22. Shock. 2010 Jun;33(6):568-75 [PMID: 19864971]
  23. Trends Immunol. 2004 Oct;25(10):536-42 [PMID: 15364056]
  24. Mol Immunol. 2008 Jun;45(11):3125-32 [PMID: 18452991]
  25. Semin Hematol. 1992 Jul;29(3):213-26 [PMID: 1641667]
  26. J Immunol. 1984 Nov;133(5):2629-33 [PMID: 6332857]
  27. Am J Pathol. 1975 Mar;78(3):525-36 [PMID: 1091153]
  28. Biochem Biophys Res Commun. 2003 May 23;305(1):28-36 [PMID: 12732192]
  29. J Immunol. 2000 Jul 15;165(2):1066-73 [PMID: 10878385]
  30. Biochemistry. 1990 Oct 9;29(40):9418-25 [PMID: 2248955]
  31. Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2511-8 [PMID: 11116046]
  32. Nat Rev Immunol. 2008 Oct;8(10):776-87 [PMID: 18802444]
  33. Blood. 2007 Mar 1;109(5):1992-7 [PMID: 17105819]
  34. Shock. 2008 Jan;29(1):25-31 [PMID: 17621257]
  35. J Biol Chem. 1981 Dec 25;256(24):12617-9 [PMID: 6458605]
  36. Br J Haematol. 2005 Nov;131(4):417-30 [PMID: 16281932]
  37. J Biol Chem. 2003 Dec 19;278(51):51059-67 [PMID: 14525995]
  38. Am J Pathol. 2002 Nov;161(5):1849-59 [PMID: 12414531]
  39. Springer Semin Immunopathol. 1983;6(2-3):231-58 [PMID: 6227099]
  40. Thromb Haemost. 2001 Jun;85(6):958-65 [PMID: 11434702]
  41. Thromb Res. 2000 May 15;98(4):323-32 [PMID: 10822079]
  42. Physiology (Bethesda). 2006 Aug;21:281-8 [PMID: 16868317]
  43. Nat Rev Immunol. 2004 Feb;4(2):133-42 [PMID: 15040586]
  44. Thromb Haemost. 1997 Feb;77(2):394-8 [PMID: 9157602]
  45. J Pharmacol Exp Ther. 2002 Mar;300(3):729-35 [PMID: 11861775]
  46. J Immunol. 2006 Oct 1;177(7):4794-802 [PMID: 16982920]
  47. Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):E107-12 [PMID: 11073863]
  48. Annu Rev Biochem. 1980;49:765-811 [PMID: 6996572]
  49. J Biochem. 1994 Nov;116(5):1013-18 [PMID: 7896727]
  50. Zentralbl Chir. 1994;119(10):683-9 [PMID: 7801706]
  51. Blood. 1997 Apr 15;89(8):2863-70 [PMID: 9108406]
  52. Trends Biochem Sci. 2002 Feb;27(2):67-74 [PMID: 11852243]
  53. PLoS One. 2007 Jul 18;2(7):e623 [PMID: 17637839]
  54. Thromb Res. 2004;114(5-6):321-7 [PMID: 15507261]
  55. Am J Pathol. 2002 May;160(5):1867-75 [PMID: 12000738]

Grants

  1. R01 GM062134-08/NIGMS NIH HHS
  2. P01 AI068730-04/NIAID NIH HHS
  3. AI068730/NIAID NIH HHS
  4. AI30040/NIAID NIH HHS
  5. N01AI30040/NIAID NIH HHS
  6. GM062134/NIGMS NIH HHS
  7. R01 AI030040/NIAID NIH HHS
  8. R01 GM062134/NIGMS NIH HHS
  9. P01 AI068730/NIAID NIH HHS
  10. R01 AI030040-15/NIAID NIH HHS

MeSH Term

Adult
Aged
Anaphylatoxins
Blood Coagulation
Blotting, Western
Chemotaxis, Leukocyte
Complement Activation
Complement System Proteins
Enzyme-Linked Immunosorbent Assay
Female
Humans
Male
Mast Cells
Middle Aged
Neutrophils
Serine Proteases
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Young Adult

Chemicals

Anaphylatoxins
Complement System Proteins
Serine Proteases

Word Cloud

Created with Highcharts 10.0.0complementcoagulationC3>C5asystemcascadesmultiplefactorsC5humancleavageC3aFXaserummolecularfibrinolysisexvivoplasminfoundproductsanaphylatoxinsactivityFurthermoreplasmacomplexwellfundamentalclinicalimplicationscontextlife-threateningtissueinjuryinflammationAssociationsproposedprecisemechanismsremainunknowncurrentstudyreportslinksvariouscentralcomponentsvitroThrombinFXIaXaIXaeffectivelycleaveMassspectrometricanalysesidentifieddisplayingidenticalweightsnativeCleavagealsoexhibitedrobustchemoattractionmastcellsneutrophilsrespectivelyEnzymaticinvestigatedclottingdefinedfollowingorder:thrombinFIXaFXIacontrolFXa-inducedsignificantlysuppressedpresenceselectiveinhibitorsfondaparinuxenoxaparinconcentration-dependentmannerAdditionactivatedrepresentedgenerationterminaldecreasedhemolyticdefinesexactconcentrationresultscomplement-mediatedlysis50%sensitizedsheeperythrocytespatientsinjuriesn=12earlyappearancecorrelationthrombin-antithrombincomplexesactivationproductpresentdatasuggestcoagulation/fibrinolysisproteasesmayactnaturalconvertasesgeneratingbiologicallyactivelinkingviadirectinteractionstermsserineproteaseMolecularintercommunicationsystems

Similar Articles

Cited By